Gerresheimer Faces Critical Reporting Deadline Amid Deepening Crisis

German pharma packager Gerresheimer faces BaFin investigations, major financial write-downs, and a March 31 deadline for its annual report, sending shares to a 10-year low.

The German pharmaceutical packaging group Gerresheimer finds itself in a precarious position, with its shares trading at multi-year lows. A confluence of regulatory scrutiny, significant financial write-downs, and delayed reporting has created a perfect storm for the company. All eyes are now fixed on a firm deadline: the certified annual report must be submitted by March 31st to avert further complications.

Financial and Regulatory Turmoil

At the heart of the company's difficulties are two parallel investigations launched by the German Federal Financial Supervisory Authority, BaFin. The first probe, already ongoing, concerns the consolidated financial statements for 2024. A second examination has now been initiated, focusing on the 2025 half-year report. Central to the inquiries are accounting practices related to "bill-and-hold" agreements, where revenues were reportedly booked prior to the physical delivery of goods.

Specific areas under review include potentially misstated lease liabilities amounting to €65.5 million and capitalized development costs of €29.4 million. Gerresheimer has acknowledged internal compliance failures, admitting that certain employees violated accounting rules. The fallout has already claimed top-level scalps, with former CEO Dietmar Siemssen and CFO Bernd Metzner departing the company.

Severe Financial Revisions

The financial repercussions are substantial. For the 2025 fiscal year, Gerresheimer anticipates impairment charges in the range of €220 to €240 million. These write-downs are primarily linked to its Sensile Medical subsidiary in Switzerland and a manufacturing facility in Chicago. Consequently, the company's adjusted EBITDA margin forecast has been slashed. The new guidance projects a margin of 16.5% to 17.5%, a notable downgrade from the previously communicated target of 18.5% to 19.0%.

Earnings per share are expected to decline by a high double-digit percentage, with the possibility of a net loss not being ruled out. Looking further ahead, management has set a revenue target of €2.3 to €2.4 billion for 2026.

Strategic Asset Sales and Closures

In a bid to stabilize its balance sheet, Gerresheimer is pursuing the sale of its US subsidiary, Centor. The investment bank Morgan Stanley has been tasked with managing the process, aiming for completion within 2026. This move, however, presents a strategic dilemma. Centor is recognized for producing high-margin packaging systems and is considered a highly profitable segment of the business. Its divestment would likely further pressure the group's already weakened margin profile.

Conversely, management has halted the planned sale of its Moulded Glass business unit. Instead, the company will proceed with the closure of its Chicago Heights plant by the end of 2026.

Share Price Collapse and Glimmers of Interest

The equity market has reacted harshly to the unfolding crisis. On February 26th, Gerresheimer's stock hit a fresh 10-year low of €15.57. Since the start of the year, the share price has collapsed by more than 31%. This represents a staggering decline of over 76% from its 52-week high of €82, recorded in March 2025.

Recently, there have been tentative signs of a rebound. The stock advanced 5.59% to €19.09 last Friday, bringing its weekly gain to nearly 14%. This slight recovery coincided with a regulatory filing showing that the CastleKnight Master Fund LP has acquired a 4.08% stake in the company, suggesting some investors may see value amidst the turmoil. Separately, the Deutsche Schutzvereinigung für Wertpapierbesitz (DSW), a German shareholder association, has announced it is examining potential claims for damages.

The Path Forward Hinges on Transparency

The submission of the audited annual report by the end of March is the immediate critical hurdle. A transparent resolution of the identified accounting issues and successful navigation of the BaFin investigations by the new leadership team could help establish a foundation for recovery. Any further delays or unexpected negative developments, however, would likely trigger another test of the recent lows. Investors will receive the next update with the quarterly report scheduled for April 16th, while the Annual General Meeting is set for June 3rd, 2026.